[Therapeutic revolution in heart failure]
A Ancion1, M L Nguyen Trung1, J Tridetti1
1Service de Cardiologie, CHU Liège, Belgique.
Revue Medicale De Liege
|June 5, 2020
Summary
Sacubitril/valsartan significantly reduces heart failure mortality and hospitalizations, marking a therapeutic advance. However, it
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure treatment has seen limited progress since the late 1990s.
- The increasing prevalence and poor prognosis of heart failure necessitate new therapeutic strategies.
- Current treatment paradigms offer limited options for certain patient subsets.
Purpose of the Study:
- To evaluate the impact of sacubitril/valsartan on heart failure outcomes.
- To assess the potential of novel therapeutic classes in managing heart failure.
- To explore the benefits and limitations of sacubitril/valsartan in diverse heart failure populations.
Main Methods:
- Review of clinical trial data and epidemiological trends in heart failure.
- Analysis of the efficacy of sacubitril/valsartan in reducing mortality and hospitalizations.
- Assessment of cardiac remodeling effects associated with sacubitril/valsartan therapy.
Main Results:
- Sacubitril/valsartan demonstrated a significant reduction in heart failure-related mortality and hospitalizations.
- Evidence suggests positive cardiac remodeling in a substantial number of patients treated with sacubitril/valsartan.
- The benefits of sacubitril/valsartan may not extend equally to patients with heart failure with preserved ejection fraction.
Conclusions:
- Sacubitril/valsartan represents a significant advancement in heart failure management, introducing a new therapeutic class.
- While promising, sacubitril/valsartan is not a definitive solution, and further research is ongoing.
- Future therapeutic developments are anticipated to build upon this initial revolution in heart failure treatment.
Related Concept Videos
01:30Heart Failure V: Medical Management
150
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
150
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
800
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
800
01:22Heart Failure VI: Adjunct Therapies
171
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
171
01:22Heart Failure Drugs: β-Blockers
670
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
670
01:22Heart Failure Drugs: Diuretics
721
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
721
01:26Heart Failure Drugs: Inotropic Agents
1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K